Role of immunocorrection therapy in comprehensive treatment of patients with inflammatory diseases of female genital organs

Aim. Analysis of gynecological diseases structure in which immunocorrection with Polyoxidonium ® was prescribed, determination of a preferential drug form (suppositories 12 mg/lyophilisate 6 mg), assessment of its clinical effectiveness. Outcomes and methods. Observational program of clinical efficacy of Polyoxidonium ® (12 mg suppositories or 6 mg lyophilisate) used along with standard treatment in 8975 women with inflammatory diseases of female genital tract in 20 regions of the Russian Federation in accordance with international standards of good epidemiological practice (GEP). Results. The overall assessment of Polyoxidonium ® used along with the standard treatment in patients with inflammatory diseases of female genitals was 4.17±0.75 points (4 – marked improvement; 5 – full recovery). The drug was significantly more effective in vaginitis (4.36±0.68 points) and cervicitis (4.40±0.74 points) compared with standard therapy. In PID the most effective drug form was lyophilisate. Conclusion. The drug is well tolerated, practically free of side effects and addiction, convenient in use and is compatible with any treatment regimen. In the treatment of lower genital tract inflammatory diseases, it is optimal to use the drug in the form of suppositories while in the treatment of PID in the form of a lyophilisate.